The article has been automatically translated into English by Google Translate from Russian and has not been edited.
Переклад цього матеріалу українською мовою з російської було автоматично здійснено сервісом Google Translate, без подальшого редагування тексту.
Bu məqalə Google Translate servisi vasitəsi ilə avtomatik olaraq rus dilindən azərbaycan dilinə tərcümə olunmuşdur. Bundan sonra mətn redaktə edilməmişdir.

Coronavirus vaccine: what success did different developers achieve

The world will return to normal life in full only with the advent of a vaccine against coronavirus, experts say. Today, it is being developed by leading pharmaceutical companies around the world. American Pfizer and German BioNTech have announced the launch of one of the most promising trials of a vaccine against COVID-19. Students in American medical schools take part in the tests. This is stated in the video "Voices of America".

Photo: Shutterstock

Michael Sikorski is ready to become part of the story. He is already the seventh medical student to receive an injection of the COVID-19 vaccine.

“I feel responsibility and responsibility as a young, healthy, and adult to take part in these trials,” says Michael.

Sikorski is included in group 361 of the first phase of vaccine trials conducted by the American company Pfizer and its German partner BioNTech. They are simultaneously testing four vaccines. The drug introduces a small amount of the genetic code of the virus in the form of RNA. The human body produces a viral protein, the immune system reacts to it as a foreign one, which causes an immune response and the production of specific antibodies.

“Now the body is ready, it has a memory, and as soon as a real virus knocks on the door, we will immediately intercept it,” explains Michael Dolsten, senior scientist at Pfizer.

The race to curb the virus involves hundreds of companies around the world. So, the American Moderna, together with the National Institute of Health, is already conducting the second phase of clinical trials: testing the effectiveness of the RNA vaccine in humans. The first phase of the test - testing its safety - was successfully completed in April.

On the subject: Everyone is looking for a vaccine from a coronavirus: spies also don’t sit idly by

Inovio, a Chinese company - CanSino Biologics, is in the test phase. Scientists from Wuhan and Beijing use the old method of introducing a passive virus in their work. Leading vaccinologists predict the emergence of an effective vaccine in October.

“The challenge is to make enough vaccine to distribute it properly.

In the meantime, scientists are testing the safety of the test serum on test participants, ”said Anthony Fauchi, director of the National Institute of Allergic and Infectious Diseases.

“Every day at 09:00 a reminder comes to my phone:“ fill out your security diary. ” I take the thermometer that was given to me, measure the temperature. Then I answer a few questions. Among them: do I have any pains, do I have a fever, swelling, sensitivity, ”Sikorski explained.

If the tests are successful, the coronavirus vaccine will appear before the end of the year, and this is an unprecedented speed in the field of immunization medicine.

Miscellaneous vaccine Educational program coronavirus Special Projects

Read also on ForumDaily:

WHO: coronavirus can become a constant infection that kills people every year

Llamas will save humanity: scientists have found a way to treat COVID-19 with animal blood

Coronavirus antibody test: why do you need to do it

Coronavirus mutated: a new strain is much more contagious than previous ones

1,4 million will die: the number of tuberculosis diseases will increase due to coronavirus

Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. And don't forget to subscribe to ForumDaily Woman and ForumDaily New York - there you will find a lot of interesting and positive information.



1041 requests in 2,052 seconds.